Know Cancer

forgot password

The Impact of Ureteral Stents on Peristalsis

19 Years
Not Enrolling
Kidney Stones,, Tumor,, Hydronephrosis

Thank you

Trial Information

The Impact of Ureteral Stents on Peristalsis

Ureteral stents are commonly used in the field of urology to maintain urinary drainage and
are inserted into ureters of patients who suffer from kidney stones, urinary tract
infections or cancer. Usually the muscle cells of the ureter contract in a coordinated
fashion (peristalsis) in order to provide urinary flow from the kidney into the bladder. By
inserting a stent these contractions are disrupted, eventually resulting in a loss of
peristalsis. This phenomena is accompanied by swelling of the kidney and pain, which are
well-known negative side effects of stents. To avoid stent-related morbidity and improve
patients care this issue needs to be investigated further. A first step is to analyse the
impact of stents on peristalsis and to possibly bring these results into context with
hypothesised molecular mechanisms involved in peristalsis.

Inclusion Criteria:

1. stone disease

2. localized tumor disease

3. hydronephrosis of unknown ethiology

4. patients who receive a prophylactic stent before a planned operation.

Exclusion Criteria:

1. Patients being septic and in a life-threatening condition before or after

2. patients with tumors in a progressive state that affect the retroperitoneum
(contralateral ureter might be affected and can not serve as a control for the
stented side)

3. patients with Morbus Ormond (same reason as above)

4. patients requiring ureteral stents bilaterally (same reason as above)

5. long-term stented patients will be excluded as we are interested in evaluating the
onset of changes in peristalsis rate which are expected to be most significant in an
acute setting.

6. patients with preexisting abnormalities/pathologies of the urinary tract e.g. reflux
disease, megaureter or bladder dysfunctions as these will likely affect our results

7. non English-speaking patients will be excluded as they will not be able to understand
the letter of consents.

Exclusion criteria for control group:

1. known preexisting pathology in the urinary tract (see above)

2. volunteers who underwent previous surgical procedures on kidney, ureter or bladder
within the past 5 years as this may change the starting position of our study

3. patients currently taking an α-blocker (alfuzosin, terazosin, doxazosin, tamsulosin,
prazosin) because these medications are known to affect peristalsis

4. patients currently taking calcium channel blocker (verapamil, diltiazem, nifedipine,
nicardipine, bepridil, mibefradil) because these medications are known to affect

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Effect of stent on ureteral peristalsis in stented ureter

Outcome Description:

before and after stent insertion (approximately 30 minutes)

Outcome Time Frame:

before and after stent insertion (approximately 30 minutes)

Safety Issue:


Principal Investigator

Ben Chew, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of British Columbia


Canada: Health Canada

Study ID:




Start Date:

December 2012

Completion Date:

December 2014

Related Keywords:

  • Kidney Stones,
  • Tumor,
  • Hydronephrosis
  • peristalsis, kidney stones, hydronephrosis, ureteral stent
  • Hydronephrosis
  • Kidney Calculi
  • Nephrolithiasis